Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co EBITDA per Employee

The EBITDA per Employee of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 31, 2026 is -30,446.95 CNY. In the previous year, EBITDA per Employee was -82,225.39 CNY — a change of -62.97% (higher).

EBITDA per Employee

-30,446.95CNY

YoY

-62.97%

Last updated:

EBITDA per Employee of Shanghai Fudan Forward S&T Co is 2025 -30,446.95 CNY. EBITDA per Employee of Shanghai Fudan Forward S&T Co was 2024 -82,225.39 CNY. It decreases by -62.97% higher compared to the previous year.

The Shanghai Fudan Forward S&T Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
53,671.58 CNY
Jan 1, 2019
47,460.05 CNY
Jan 1, 2020
-9,850.49 CNY
Jan 1, 2021
-34,749.26 CNY
Jan 1, 2022
14,097.21 CNY
Jan 1, 2023
18,400.58 CNY
Jan 1, 2024
-82,225.39 CNY
Jan 1, 2025
-30,446.95 CNY
The Shanghai Fudan Forward S&T Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-30,446.95CNY-62.97%
-82,225.39CNY-546.86%
18,400.58CNY+30.53%
14,097.21CNY-140.57%
-34,749.26CNY+252.77%
-9,850.49CNY-120.76%
47,460.05CNY-11.57%
53,671.58CNY+13.60%
47,246.36CNY+13.22%
41,728.08CNY-1.30%
42,275.71CNY+29.09%
32,750.06CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

EBITDA per Employee of Shanghai Fudan Forward S&T Co is -30,446.95 CNY in 2025.

EBITDA per Employee of Shanghai Fudan Forward S&T Co changed from -82,225.39 CNY to -30,446.95 CNY, representing a -62.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Shanghai Fudan Forward S&T Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Shanghai Fudan Forward S&T Co

All Key Metrics — Shanghai Fudan Forward S&T Co